Your search found 1111 Results

  1. 1
    Peer Reviewed

    Hormonal Contraceptives for Endometrial Cancer Prevention in Obese and High-Risk Women in Virginia.

    Horst KE; Modesitt SC

    Southern Medical Journal. 2016 Oct; 109(10):621-627.

    Add to my documents.
  2. 2
    Peer Reviewed

    Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.

    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ 3rd

    Gynecologic Oncology. 2016 Feb; 140(2):234-8.

    Add to my documents.
  3. 3
    Peer Reviewed

    Surveillance and Care of the Gynecologic Cancer Survivor.

    Faubion SS; MacLaughlin KL; Long ME; Pruthi S; Casey PM

    Journal of Women's Health. 2015 Nov; 24(11):899-906.

    Add to my documents.
  4. 4
    Peer Reviewed

    Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.

    Dominick S; Hickey M; Chin J; Su HI

    Cochrane Database of Systematic Reviews. 2015; 12:CD007245.

    Add to my documents.
  5. 5

    Oral contraception and risk of endometrial cancer.

    Mueck AO; Seeger H; Ruan X

    Open Access Journal of Contraception. 2011 Oct 18; 2:127-136.

    Add to my documents.
  6. 6
    Peer Reviewed

    Progesterone-based intrauterine device use is associated with a thinner apical layer of the human ectocervical epithelium and a lower ZO-1 mRNA expression.

    Tjernlund A; Carias AM; Andersson S; Gustafsson-Sanchez S; Rohl M; Petersson P; Introini A; Hope TJ; Broliden K

    Biology of Reproduction. 2015 Mar; 92(3):68.

    Add to my documents.
  7. 7
    Peer Reviewed

    Endometrial cancer with progestagen and oestrogen oral contraceptives.

    Grant EC

    Lancet. Oncology. 2015 Nov; 16(15):e527.

    Add to my documents.
  8. 8
    Peer Reviewed

    Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.

    Collaborative Group on Epidemiological Studies on Endometrial Cancer

    Lancet. Oncology. 2015 Aug 4;

    Add to my documents.
  9. 9
    Peer Reviewed

    Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device +/- metformin +/- weight loss in endometrial cancer (feMME) trial.

    Hawkes AL; Quinn M; Gebski V; Armes J; Brennan D; Janda M; Obermair A

    Contemporary Clinical Trials. 2014 Sep; 39(1):14-21.

    Add to my documents.
  10. 10
    Peer Reviewed

    Rapid presentation of endometrial carcinoma after removal of an intrauterine device.

    Lin LT; Tsui KH; Cheng JT; Yen MS; Li YT; Wang PH

    Taiwanese Journal of Obstetrics and Gynecology. 2014 Jun; 53(2):267-9.

    Add to my documents.
  11. 11
    Peer Reviewed

    Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium.

    Felix AS; Gaudet MM; La Vecchia C; Nagle CM; Shu XO; Weiderpass E; Adami HO; Beresford S; Bernstein L; Chen C; Cook LS; De Vivo I; Doherty JA; Friedenreich CM; Gapstur SM; Hill D; Horn-Ross PL; Lacey JV; Levi F; Liang X; Lu L; Magliocco A; McCann SE; Negri E; Olson SH; Palmer JR; Patel AV; Petruzella S; Prescott J; Risch HA; Rosenberg L; Sherman ME; Spurdle AB; Webb PM; Wise LA; Xiang YB; Xu W; Yang HP; Yu H; Zeleniuch-Jacquotte A; Brinton LA

    International Journal of Cancer. 2015 Mar 1; 136(5):E410-22.

    Add to my documents.
  12. 12

    Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.

    Davidson BA; Moorman PG

    Expert Opinion On Drug Safety. 2014 Aug 22; 1-8.

    Add to my documents.
  13. 13
    Peer Reviewed

    Long-term outcomes after progestogen treatment for early endometrial cancer.

    Cade TJ; Quinn MA; Rome RM; Neesham D

    Australian and New Zealand Journal of Obstetrics & Gynaecology. 2013 Dec; 53(6):566-70.

    Add to my documents.
  14. 14
    Peer Reviewed

    Hormonal contraceptive use for endometrial cancer prevention: physician attitudes and practices.

    Horst KE; Modesitt SC

    Obstetrics and Gynecology. 2014 May; 123 Suppl 1:183S.

    Add to my documents.
  15. 15
    Peer Reviewed

    Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.

    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D

    American Journal of Obstetrics and Gynecology. 2014 Mar; 210(3):255.e1-4.

    Add to my documents.
  16. 16
    Peer Reviewed

    Cancer risk and PCOS.

    Dumesic DA; Lobo RA

    Steroids. 2013 Aug; 78(8):782-5.

    Add to my documents.
  17. 17
    Peer Reviewed

    Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.

    Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH

    American Journal of Obstetrics and Gynecology. 2013 Oct; 209(4):358.e1-4.

    Add to my documents.
  18. 18
    Peer Reviewed

    Hormone Contraception Before the First Birth and Endometrial Cancer Risk.

    Cook LS; Dong Y; Round PJ; Huang X; Magliocco AM; Friedenreich CM

    Cancer Epidemiology, Biomarkers and Prevention. 2013 Dec 10;

    Add to my documents.
  19. 19
    Peer Reviewed

    Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.

    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N

    Cochrane Database of Systematic Reviews. 2013; 6:CD009458.

    Add to my documents.
  20. 20
    Peer Reviewed

    Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review.

    Gierisch JM; Coeytaux RR; Peragallo Urrutia R; Havrilesky LJ; Moorman PG; Lowery WJ; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER

    Cancer Epidemiology, Biomarkers and Prevention. 2013 Sep 6;

    Add to my documents.
  21. 21
    Peer Reviewed

    Prospective, Multi-center Randomized Intermediate Biomarker Study of Oral Contraceptive vs. Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome.

    Lu KH; Loose DS; Yates MS; Nogueras-Gonzalez GM; Munsell MF; Chen LM; Lynch H; Cornelison T; Boyd-Rogers S; Rubin M; Daniels MS; Conrad P; Milbourne A; Gershenson DM; Broaddus RR

    Cancer Prevention Research. 2013 May 2;

    Add to my documents.
  22. 22
    Peer Reviewed

    An aggregated analysis of hormonal factors and endometrial cancer risk by parity.

    Schonfeld SJ; Hartge P; Pfeiffer RM; Freedman DM; Greenlee RT; Linet MS; Park Y; Schairer C; Visvanathan K; Lacey JV Jr

    Cancer. 2013 Apr 1; 119(7):1393-401.

    Add to my documents.
  23. 23
    Peer Reviewed

    Progestin potency - assessment and relevance to choice or oral contraceptives.

    Goldstuck N

    Middle East Fertility Society Journal. 2011 Dec; 16(4):248-253.

    Add to my documents.
  24. 24
    Peer Reviewed

    Hormonal contraceptives and cancer risk [letter]

    Richman S

    Contraception. 2012 Dec; 86(6):772.

    Add to my documents.
  25. 25
    Peer Reviewed

    Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study.

    AlHilli MM; Dowdy SC; Weaver AL; St Sauver JL; Keeney GL; Mariani A; Podratz KC; Bakkum-Gamez JN

    Gynecologic Oncology. 2012 Apr; 125(1):109-13.

    Add to my documents.